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Abstract 
Introduction: The primary objective of this study was to explore the association of pro-inflammatory cytokines with quantitative computed 
tomography (QCT)-measured bone mineral density (BMD) and its sexual difference in a Chinese population. 
Material and methods: In a cross-sectional study, a total of 85 participants aged 48–85 years were recruited and classified into three groups: 
normal bone mass with BMD > 120 mg/cm3, osteopaenia with BMD 80–120 mg/cm3, and osteoporosis with BMD < 80 mg/cm3. ANOVA 
analysis and multivariable ordinal logistic regression was used to estimate the associations of interest.
Results: The proportions of osteoporosis, osteopaenia, and normal BMD were 29.41% (25), 37.65% (32), and 32.94% (28), respectively. 
Males had the highest proportion of osteopaenia while females had osteoporosis (p < 0.01). In contrast with the null findings in males, 
significant statistical difference was observed in females. Compared to the normal BMD, the OR for increasing IL-6 level of decreasing 
BMD groups (osteoporosis and/or osteopaenia) was 9.50 (95% CI: 1.44–62.80). TNF-a and IL-17 tended to show an increased risk (OR > 1) 
but did not reach significance. Current OR result cannot confirm these relationships of IL-1b, and ORs of PAI-1 and MCP-1 are too close 
to 1 to determine the practical meaning.
Conclusions: IL-6 is an obviously independent risk factor of QCT-measured osteoporosis in Chinese females. Sex hormones and fat-related 
factors are important confounders in the research of osteoimmunology. (Endokrynol Pol 2019; 70 (3): 248–254)
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Introduction
Osteoporosis is prevalent in the middle-aged and older 
populations with more than 200 million individuals 
affected worldwide [1]. In China, about 69.44 million 
people aged 50 years or over suffer from osteoporosis, 
while 210 million have low bone mass, and the number 
of osteoporosis cases is expected to rise to 286.6 million 
by 2020 [2]. As one of the consequences of osteoporo-
sis, fractures are becoming a severe disease burden to 
society. The medical costs of 2015, 2035, and 2050 for 
primary osteoporosis fracture (wrist, vertebral body, 
and hip) will be as high as 1.1 billion, 1.9 billion, and 
2.4 billion dollars, respectively [3]. Hence, active efforts 
to prevent osteoporosis are necessary.
Multiple risk factors have been recognised to con-
tribute to the occurrence and development of osteopo-
rosis, including sex, age, obesity, diabetes, and trauma 
[4]. Several basic studies show that innate and adaptive 
immunity cells produce inflammatory cytokines that 
not only perpetuate inflammation but also may activate 
bone degradation and inhibit bone formation. Indeed, 
the degree of the inflammation correlates with the ex-
tent of local and systemic bone loss [5, 6]. Unfortunately, 
population-based evidence about pro-inflammatory 
cytokines and osteoporosis is still rare and too limited 
to draw conclusions.
In addition, bone mineral density (BMD) is a sur-
rogate indicator of bone strength, which plays an im-
portant role in the management of osteoporosis and 
related fractures. Different from areal BMD measured 
by dual-energy X-ray absorptiometry (DXA), bone 
mineral density by quantitative computed tomography 
(QCT) is a volumetric measure of the vertebral trabecu-
lar bone. This approach is convenient for the assessment 
of BMD during routine abdominal and/or lung CT 
scans, and for the identification of patients who have 
an increased risk of fracture with diagnostic CT scan-
ning. Given the high turnover rate of trabecular bone 
compared to cortical bone, BMD calculated from QCT 
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Statistical analysis
Data were expressed as mean ± SD for continuous variables and 
percentage (%) for categorical variables. The significant difference 
in continuous and categorical variables was tested by a one-
way ANOVA and a chi-square test, respectively, comparing the 
distribution of three groups of BMD. A non-parametric test was 
performed if the model of the ANOVA was not satisfied. Multivari-
able ordinal logistic regression was used to assess the association 
of gender-specific plasma pro-inflammatory cytokines and three 
groups of BMD, and the odds ratio (OR) and 95% confidence 
intervals (CIs) were calculated. All analyses were conducted us-
ing SPSS 19.0 for windows (serial number: 5076595) after being 
double entered. A two-sided P value < 0.05 was considered 
statistically significant.
Results
A total of 85 subjects with complete inflammation 
factors and complete QCT data were included in our 
analysis, with 40.00% (34) being men. The mean age was 
63.24 ± 7.4 years (48–85 years). BMD ranged from 24.30 
to 204.15, and the proportions of osteoporosis, osteo-
paenia, and normal BMD were 29.41% (25), 37.65% (32), 
and 32.94% (28), respectively. Gender-specific distribu-
tion of each BMD group is presented in Figure 1. The 
distribution of BMD varied in gender (p < 0.01). Males 
had the highest proportion of osteopaenia (47.06%), 
while females had osteoporosis (39.22%).
Clinical features of each BMD group
The general condition and all tested clinical features of 
participants in the three BMD groups were compared 
(see Tab. I). Participants with osteoporosis had the low-
est test values in CRE (p = 0.004) and the oldest age 
(p < 0.001). U-TAT and TP had a decreasing trend, while 
GLU and TG increased gradually from normal BMD 
to osteoporosis, but no significant statistical difference 
was found (p > 0.05).
offers substantially higher sensitivity [7, 8]. However, 
studies of osteoporosis using QCT are far fewer than 
research projects using DXA, considering that QCT is 
a newly developed technic.
Therefore, in this cross-sectional study, we used the 
QCT-measured BMD and the levels of related inflam-
matory cytokines to explore their gender-specific asso-
ciation, based on a middle-aged and older population 
in Beijing, China.
Material and methods
Study population
The participants of this study were a subset of the PURE CASH 
study population in the Beijing Jishuitan hospital. The subjects of 
the PURE CASH study and study protocol were reported previ-
ously (QIMS paper) [8, 9]. During the fourth follow-up visit, blood 
samples were collected and QCT scans were performed. The 
study protocol was approved by the Ethics Committee of Beijing 
Jishuitan hospital.
QCT measurement
As part of the protocols of the PURE CASH China study, all 
subjects underwent abdominal QCT scans. All QCT scans and 
image analyses were performed in the department of Radiology, 
Beijing Jishuitan Hospital. The details of the QCT acquisition were 
reported previously [8]. Briefly, a standard abdominal CT scan 
was performed for each of the subjects on a Toshiba 64-slice or on 
an 80-slice CT scanner with a Mindways QCT pro (Mindways, 
Austin, TX, USA) calibration phantom positioned under the back. 
The BMD of L1-3 lumbar vertebral body was measured with the 
Mindways QCT pro v5 software according to the manufactory’s 
instruction.
Adipose tissue measurement
The CT volumetric dataset was transferred to a Mindways QCT 
workstation and the measurement of abdominal adipose tissue 
was performed by trained and qualified radiologists. The details of 
adipose tissue measurement of each slice were described in earlier 
publications [9]. Six slices at each intervertebral space from T12 /
L1 to L5 /S1, as well as an extra slice at the umbilicus level, were 
measured. Total adipose tissue (TAT) and visceral adipose tissue 
(VAT) area (cm2) were semi-automatically measured by the tissue 
composition module of the software (Mindways, Austin, TX, USA).
Plasma measurement and other data collection
All physical examinations (blood pressure, height, and weight) and 
sample tests were measured according to a standardised protocol 
and conducted by trained physicians. Tumour necrosis factor 
a (TNF-a), interleukin 1b (IL-1b), IL-6, IL-17, human monocyte 
chemoattractant protein-1 (MCP-1), and plasminogen activator 
inhibitor-1 (PAI-1) were measured by a multi-factor detection instru-
ment (MACPIX, LUMINEX) using HADCYMAG-61K MILLIPLEX 
MAP Human Adipocyte Magnetic Bead Panel-Endocrine Multiplex 
Assay. The fully automatic multifunctional enzyme labelling instru-
ment used was a MULTISKAN MK3 (Thermo, USA).
Definitions of osteoporosis and BMI
Participants were categorised into three groups according the 
measurement of BMD: (1) normal bone mass: BMD > 120 mg/cm3, 
(2) osteopaenia: BMD 80–120 mg/cm3, and (3) osteoporosis: BMD 
< 80 mg/cm3 [10, 11]. Body mass index (BMI) was calculated as 
weight (kg) divided by height squared (m2).
Figure 1. Gender-specific distribution of each BMD group. 
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Gender-specific comparison of pro-inflammatory 
cytokines in different BMD groups
The distribution of pro-inflammatory cytokines in dif-
ferent BMD groups by gender is shown in Table II. In 
females, the level of IL-6 was significantly different in 
each BMD group (p = 0.028), while the level of TNF-
a showed an increasing trend with decreasing BMD 
(p = 0.063). The levels of MCP-1, TNF-a, and IL-17 in 
osteopaenia and osteoporosis were higher than the 
normal, while IL-1b only increased in the osteopaenia 
group, but all with no statistical significance. No distinct 
difference could be observed in males.
The gender-difference of pro-inflammatory cyto-
kines in each BMD group was also compared. Males 
in the normal BMD group had clearly higher TNF-a, 
IL-1b, and IL-6 levels than the females (p < 0.05). And 
in the osteoporosis group, IL-17 levels were also higher 
in males (p < 0.05).
ORs of pro-inflammatory cytokines and different 
BMD groups
The ORs for increasing levels of pro-inflammatory 
cytokines with decreasing BMD group are shown in 
Table III. The findings did not vary remarkably when 
all participants were analysed.
In contrast to the null findings of the males, a sig-
nificant statistical difference was observed in females 
after further adjustment by gender and sex hormones in 
Model 2. Compared to the normal BMD group, the OR 
for the decreasing BMD group (osteopaenia and/or os-
teoporosis) with increasing levels of IL-1b was 0.50 (95% 
CI: 0.25–0.99), and it remained significant (OR = 0.03, 
95% CI: 0.002, 0.042) after all adjustments in Model 3. 
Meanwhile, an apparent association was found in IL-6, 
PAI-1, and MCP-1 in females after all adjustment; the 
adjusted ORs were 9.50 (95% CI: 1.44–62.80), 1.001 (95% 
CI: 1.000–1.002), and 0.97 (95% CI: 0.94–1.00), respec-
Table I. Characteristics of the participants in each BMD group
Normal BMD (n = 28) Osteopaenia (n = 32) Osteoporosis (n = 25) Total (n = 85) p value
General conditions
Age 59.07 ± 7.21 63.91 ± 6.52 67.04 ± 6.52 63.24 ± 7.4 0.000
BMI 25.77 ± 4.58 26.51 ± 4.02 25.92 ± 4.50 26.10 ± 4.29 0.829
SBP 132.12 ± 16.79 139.02 ± 15.15 139.08 ± 17.96 136.67 ± 16.59 0.228
DBP 77.04 ± 7.48 76.8 ± 9.23 76.6 ± 8.91 76.83 ± 8.47 0.985
Pro-inflammatory factors
MCP-1 209.4 ± 74.86 227.17 ± 65.38 225.31 ± 86.45 220.77 ± 74.69 0.619
TNF-a 2.71 ± 0.99 2.68 ± 0.76 2.75 ± 0.79 2.71 ± 0.84 0.950
IL-1b 1.09 ± 1.51 1.77 ± 3.1 0.74 ± 0.26 1.24 ± 2.12 0.099
IL-6 3.85 ± 5.94 4.58 ± 4.06 3.19 ± 1.14 3.93 ± 4.26 0.476
IL-17 11.05 ± 17.27 16.43 ± 32.31 15.71 ± 21.33 14.45 ± 24.84 0.676
PAI-1 16698.46 ± 3581.24 14509.47 ± 3810.76 15131.72 ± 4026.12 15413.56 ± 3872.77 0.083
Adipose volume
L2/3 TAT 329.84 ± 119.24 339.83 ± 106.39 328.76 ± 120.23 333.28 ± 113.59 0.920
L2/3 VAT 190.12 ± 78.47 199.58 ± 73.43 186.09 ± 76.97 192.5 ± 75.46 0.787
U-TAT 361.82 ± 133.35 369.32 ± 103.6 396.22 ± 118.66 374.76 ± 117.91 0.545
U-VAT 165.05 ± 52.32 162.06 ± 52.83 162.00 ± 54.76 163.03 ± 52.62 0.970
Regular examinations
ALT 17.36 ± 6.97 20.92 ± 9.98 16.84 ± 8.69 18.55 ± 8.8 0.151
TP 72.26 ± 4.53 73.78 ± 4.05 74.62 ± 3.56 73.53 ± 4.15 0.105
CRE 71.04 ± 16.63 69.66 ± 10.69 59.52 ± 12.36 67.13 ± 14.13 0.004
GLU 6.65 ± 3.08 6.30 ± 2.10 5.96 ± 1.97 6.32 ± 2.42 0.586
T-CHO 5.03 ± 0.83 4.99 ± 0.99 4.99 ± 0.92 5.01 ± 0.91 0.982
TG 1.93 ± 1.29 1.74 ± 1.15 1.35 ± 0.61 1.69 ± 1.09 0.146
BMD — bone mineral density: normal BMD = BMD > 120 mg/cm3; osteopaenia = BMD 80–120 mg/cm3; osteoporosis = BMD < 80 mg/cm3; BMI — body mass 
index; SBP — systolic blood pressure; DBP — diastolic blood pressure; MCP-1 — human monocyte chemoattractant protein-1; TNF-a — tumour necrosis factor a; 
IL — interleukin; PAI-1 — plasminogen activator inhibitor-1; L2/3 TAT — L2/3 layer of total adipose tissue; L2/3 VAT — L2/3 layer of visceral adipose tissue; U-TAT 
— umbilicus level of total adipose tissue; U-VAT — umbilicus level of visceral adipose tissue; ALT — alamine aminotransferase; TP — total protein; CRE — serum 
creatinine; GLU — fasting blood glucose; T-CHO — total cholesterol; TG — triglyceride
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Table III. Sex-specific association of pro-inflammatory cytokines and BMD groups
Female (n = 51) Male (n = 34) Total (n = 85)
OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value
Model 1
MCP-1 1.00 (0.99,1.01) 0.659 1.01 (0.99,1.03) 0.296 1.00 (1.001.01) 0.775
TNF-a 1.95 (0.65,5.82) 0.230 1.72 (0.48,6.22) 0.409 1.08 (0.57,2.07) 0.806
IL-1b 0.66 (0.35,1.24) 0.198 0.57 (0.19,1.71) 0.312 0.80 (0.57,1.13) 0.207
IL-6 1.15 (0.72,1.80) 0.555 0.47 (0.20,1.15) 0.098 1.01 (0.80,1.28) 0.917
IL-17 1.03 (0.99,1.07) 0.122 1.07 (0.99,1.15) 0.071 1.01 (1.00,1.03) 0.137
PAI-1 1.00 (1.00,1.00) 0.963 1.00 (1.00,1.00) 0.111 1.00 (1.00,1.00) 0.173
Model 2
MCP-1 0.99 (0.98,1.00) 0.106 1.03 (0.98,1.08) 0.287 1.00 (1.00,1.01) 0.748
TNF-a 3.47 (0.95,12.63) 0.059 9.98 (0.51,196.76) 0.130 1.14 (0.58,2.24) 0.706
IL-1b 0.50 (0.25,0.99) 0.047 0.56 (0.12,2.63) 0.465 0.82 (0.59,1.14) 0.244
IL-6 1.52 (0.90,2.57) 0.114 0.28 (0.06,1.37) 0.115 1.02 (0.85,1.23) 0.835
IL-17 1.03 (0.99,1.08) 0.117 1.09 (0.98,1.21) 0.129 1.01 (0.99,1.03) 0.225
PAI-1 1.00 (1.00,1.00) 0.323 1.00 (1.00,1.00) 0.092 1.00 (1.00,1.00) 0.217
Model 3
MCP-1 0.97 (0.94,1.00) 0.031 1.07 (0.01,82.85) 0.976 1.00 (1.00,1.01) 0.309
TNF-a 32.27 (0.67,1560.87) 0.079 1.44 E +09 (0,3.54E+40) 0.568 1.15 (0.52,2.54) 0.729
IL-1b 0.03 (0.002,0.042) 0.010 0 (0,3.84E+57) 0.921 0.70 (0.49,1.01) 0.053
IL-6 9.50 (1.44,62.80) 0.019 0.02 (0,8.74 E+07) 0.739 1.07 (0.88,1.30) 0.484
IL-17 1.10 (1.00,1.22) 0.054 1.37 (0.01,145.91) 0.895 1.02 (1.00,1.04) 0.100
PAI-1 1.001 (1.000,1.002) 0.024 1.00 (0.97,1.03) 0.920 1.00 (1.00,1.00) 0.291
Model 1 adjusted for age and regular examinations. Model 2 adjusted for Model 1, sex and sex hormones. Model 3 adjusted for Model 2, adipocytokines and adipose 
volume. All based on normal BMD group. BMD — bone mineral density; OR — odds ratio; CI — confidence interval
Table II. Gender-specific comparison of pro-inflammatory cytokines in each BMD group
Normal BMD (n = 28) Osteopaenia (n = 32) Osteoporosis (n = 25) Total (n = 85) p value
Female
MCP-1 201.08 ± 79.54 229.34 ± 82.27 226.64 ± 95.37 219.97 ± 86.09 0.606
TNF-a 2.36 ± 0.65 2.80 ± 0.61 2.89 ± 0.72 2.71 ± 0.69 0.063
IL-1b 0.65 ± 0.17 1.94 ± 3.97 0.67 ± 0.11 1.06 ± 2.26 0.403
IL-6 2.35 ± 1.26 5.39 ± 5.2 3.27 ± 1.15 3.66 ± 3.26 0.028
IL-17 7.36 ± 3.03 14.2 ± 17.69 15.3 ± 23.92 12.62 ± 18.05 0.407
PAI-1 16675.93 ± 3693.27 14165.25 ± 3492.85 15221.25 ± 3914.76 15317.8 ± 3779.56 0.181
Male
MCP-1 218.99 ± 71.01 225.00 ± 45.32 220.01 ± 39.94 221.97 ± 54.49 0.956
TNF-a 3.11 ± 1.17* 2.56 ± 0.89 2.2 ± 0.89 2.72 ± 1.03 0.170
IL-1b 1.61 ± 2.13** 1.60 ± 2.02 0.98 ± 0.51 1.51 ± 1.89* 0.805
IL-6 5.59 ± 8.45* 3.76 ± 2.36 2.88 ± 1.18 4.33 ± 5.45 0.559
IL-17 15.32 ± 24.97 18.65 ± 42.83 17.37 ± 3.05* 17.19 ± 32.62 0.965
PAI-1 16724.46 ± 3597.49 14853.69 ± 4190.36 14773.6 ± 4925.62 15557.21 ± 4061.79 0.432
Normal BMD = BMD > 120 mg/cm3; osteopaenia = BMD 80–120 mg/cm3; osteoporosis = BMD < 80 mg/cm3; BMI — body mass index; SBP — systolic blood 
pressure; DBP — diastolic blood pressure; MCP-1 — human monocyte chemoattractant protein-1; TNF-a — tumour necrosis factor a; IL — interleukin; 
PAI-1 — plasminogen activator inhibitor-1. Male vs. female, *p < 0.05 ** p < 0.01
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tively. TNF-a and IL-17 tended to show an increased 
risk (OR > 1) but did not reach significance.
Discussion
To the best of our knowledge, our study is the first to 
use QCT to demonstrate the sex-specific relationship 
between pro-inflammatory cytokines and BMD in 
a Chinese population. We found that IL-6 is a risk fac-
tor for osteoporosis in the Chinese female population. 
And sex hormones and visceral obesity are important 
confounding factors.
Osteoporosis is one of the most common inflamma-
tory bone-loss conditions, and it has been estimated that 
more than 50% of women and 30% of men over the age 
of 50 years are susceptible to fractures and bone loss 
[12]. In our study, participants with osteoporosis were 
characterised by older age, higher blood pressure, and 
more metabolic abnormalities. The lack of male osteo-
porosis might because of obviously higher prevalence 
osteoporosis in females, especially postmenopausal 
female deficiency of gonadal function. Clearly, it was 
essential to stratify the analysis by sex and adjust the 
effect of age.
Many basic studies have concerned the relation-
ship between bone and immune systems, and been 
called “osteoimmunology”, since the early 1970s [1]. 
Pro-inflammatory cytokines, which are secreted mainly 
by macrophages, synovial fibroblasts, and lymphocytes, 
break the balance of bone homeostasis, typically re-
sulting in a bone loss and erosion [4]. IL-6 and TNF-a 
inhibit bone-forming osteoblast cells, and TNF-a, 
IL-6, M-CSF, and MCP-1 can contribute to osteoclast 
recruitment, maturation, and inhibit osteoclast apop-
tosis [13]. Shan-Shan Rao et al. found that magnesium 
silicate-treated mice exhibited a significant increase in 
the expression of various pro-inflammatory cytokines 
(including IL-1b, IL-6, and TNF-a) and accumulation of 
pro-inflammatory macrophages in the bone marrow [6]. 
IL-6, IL-17, and IL-23 were considered to play a key role 
in the pathogenesis of obesity-related osteoarthritis [14].
The present study is the first to use QCT to provide 
evidence that each unit increase in level of IL-6 was as-
sociated with a nine-fold higher risk of low bone mass 
and osteoporosis in females, independent of age, sex 
hormones, adipocytokines, and other potentially con-
founding factors. The level of IL-6 is extremely low in 
healthy people and gradually increases with increasing 
of age or menopause [15]. IL-6 can affect the early stage 
of osteoclasts, stimulate the proliferation and division 
of osteoclast precursors, increase the number of osteo-
clasts, and promote the formation of osteoclast pits. It 
can also increase the release of collagenase to promote 
matrix degradation and affect osteoblast activity [16]. 
In a clinical study, Yan L et al. reported that the GG 
genotype of the –634C/G polymorphism in IL-6 appears 
to play a role in reducing BMD, which affects normal 
bone metabolism and leads to osteoporosis [17].
The current OR results cannot confirm the relation-
ships of IL-1b, which sit on the opposite ends of existing 
biological mechanisms. Evidence has shown the nega-
tive effects of IL-1b on the occurrence and development 
of osteoporosis [18]. Chen HY et al. reported that the 
Taq I IL-1b exon 5 gene polymorphism is associated 
with reduced BMD and predisposes women to osteo-
porosis at the lumbar spine [19]. The compound effects 
between IL-1b and sex hormones and metabolism 
might be another reason. As a result, even though the 
P value is statistically significant, practical value and 
reliability are limited from a clinical perspective, and 
more population-based studies are needed to prove 
this relationship.
Current basic studies have also shown that IL-17 en-
hances osteoclastogenesis by stimulating osteocytes and 
osteoblasts, and it potentiates osteoclastogenic activity 
via upregulation of receptor activator of NF-kB (RANK) 
production to produce higher levels of RANKL [20]. In 
our analysis, IL-17 tended to show an increased risk 
(OR > 1), but without statistical significance owing to 
the limited sample size. Similar happens to TNF-a. The 
ORs of PAI-1 and MCP-1 are too close to 1 to determine 
the practical meaning. All poor practice and statistic 
of these pro-inflammatory cytokines might due to the 
complicated mutual effects. For example, Lacativa P et 
al. revealed that IL-1b has an intimate relationship with 
TNF-a, and many effects of TNF-a are upregulated 
by IL-1b during inflammatory osteoclastogenesis [21]. 
Rosuvastatin could decrease both spontaneous and 
IL-1b-induced IL-6 mRNA expression in osteoblasts [22].
In our gradually modified logistic models, no sig-
nificance presented when only the effect of age and 
regular examinations were controlled. Obviously, 
significant statistics appeared after further adjustment 
of sex hormone, adipocytokines and adipose volume. 
In other words, osteoimmunology-related researches 
need to pay attention to the confounding effects of sex 
hormones and fat-related factors in case of false-neg-
ative results. Current available studies have revealed 
their influence and underlying mechanisms. A study 
surveying 455 participants with menopause showed 
that women with osteoporosis had lower levels of 
oestrogen and higher levels of oxidative stress, when 
compared with non-osteoporosis subjects [23]. Once 
there was a lack of oestrogen, monocyte-produced 
TNF-a and lymphocyte-produced TNF-b would 
rapidly increase, indirectly activating the mature of 
osteoclasts and other cytokines like lL-6 to promote 
proliferation of osteoclast precursors [24]. Obesity 
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is also correlated with inflammation. Adipose tis-
sue can release pro-inflammatory cytokines like 
TNF-a and IL-6, and, through the signals of TGF-b 
or RANK/RANKL to facilitate the activation and dif-
ferentiation of osteoclast, inhibit osteoclast apoptosis, 
and promote osteogenesis absorption [25].
Several limitations in this study need to be consid-
ered. First, the temporal and casual relationship could 
not be assessed in a cross-sectional design. Second, 
although multiple variables were adjusted, other con-
founding factors, such as alcohol intake, menopausal 
age, lifestyle habits, and recent usage of medicines, 
may exist. Third, the changes in pro-inflammatory 
mediator levels in blood are not as obvious as in bone; 
only the serum concentration of IL-6 was found to be 
marked risk factor. Also, one of the reasons may be 
the small sample size. Finally, population-based links 
between inflammatory factors and osteoporosis are 
still not fully elucidated. Long-term and large-scale 
population-based studies are therefore needed to reveal 
such associations and to explore the role of the immune 
system in osteoporosis.
Conclusions
IL-6 is an independent risk factor of osteoporosis mea-
sured by QCT in middle-aged and older females in 
China. Sex hormones and fat-related factors are impor-
tant confounders in the research of osteoimmunology.
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